Triggering of Toll-like Receptors in Old Individuals. Relevance for Vaccination

Author(s): Nahid Zareian, Stefano Aprile, Laura Cristaldi, Mattia Emanuela Ligotti, Sonya Vasto, Farzin Farzaneh*.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 39 , 2019

Become EABM
Become Reviewer

Abstract:

Aging is characterized by a general decline in a range of physiological functions, with a consequent increase in the risk of developing a variety of chronic diseases and geriatric syndromes. Additionally, increasing age is accompanied by a progressive decline in both innate and acquired immune system, referred to as immunosenescence. This impaired ability to mount an efficient immune response after exposure to microorganisms or vaccines represents a major challenge in acquiring protection against pathogens in aging. Therefore, there is still a great need for vaccines that are tailored to optimally stimulate the aged immune system, thus promoting more successful aging. Various strategies can be used to improve vaccine efficacy in old people. Despite this, metaanalyses have clearly shown that the magnitude of protection obtained remains lower in older adults. Recent studies show that stimulation of Toll-like receptors, using stimulatory ligands, can enhance vaccine efficacy by a number of mechanisms, including the activation of innate immune cells and the consequent production of inflammatory cytokines. Therefore, a possible strategy for more effective vaccination in the older population is the triggering of multiple TLRs, using a combined adjuvant for the synergistic activation of cellular immunity. Preliminary in vitro data suggest that in humans the presence of multiple TLR agonists can result in the greater stimulation of antigen-specific immune responses in immune cells both in the young healthy and in the immune senescent older donors. These data suggest that appropriately selected combinations of TLR agonists could enhance the efficacy of vaccination mediated immunity in older people.

Keywords: Aging, cytokines, dendritic cells, immunosenescence, TLR, vaccination.

[1]
WHO. Ageing and health World Health Organization Available at: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health
[2]
Canning D. The causes and consequences of demographic transition. Popul Stud (Camb) 2011; 65(3): 353-61.
[http://dx.doi.org/10.1080/00324728.2011.611372] [PMID: 21973179]
[3]
Omran AR. The epidemiologic transition: a theory of the epidemiology of population change. 1971. Milbank Q 2005; 83(4): 731-57.
[http://dx.doi.org/10.1111/j.1468-0009.2005.00398.x] [PMID: 16279965]
[4]
Avery P, Barzilai N, Benetos A, et al. Ageing, longevity, exceptional longevity and related genetic and non genetics markers: panel statement. Curr Vasc Pharmacol 2014; 12(5): 659-61.
[http://dx.doi.org/10.2174/1570161111666131219101226] [PMID: 24350929]
[5]
Effros RB. Roy Walford and the immunologic theory of aging. Immun Ageing 2005; 2(1): 7.
[http://dx.doi.org/10.1186/1742-4933-2-7] [PMID: 15850487]
[6]
Caruso C, Vasto S. Immunity and Aging. In: Ratcliffe MJH, Ed. Encyclopedia of Immunobiology. 2016; Vol. 5: pp. 127-32.
[http://dx.doi.org/10.1016/B978-0-12-374279-7.19003-4]]
[7]
Walford RL. The Immunologic theory of aging. Copenhagen: Munksgaard 1969; p. 2549771.
[http://dx.doi.org/10.1111/j.1600-065X.1969.tb00210.x]
[8]
Vasto S, Caruso C. Immunity & Ageing: a new journal looking at ageing from an immunological point of view. Immun Ageing 2004; 1(1): 1.
[http://dx.doi.org/10.1186/1742-4933-1-1] [PMID: 15679921]
[9]
Accardi G, Caruso C. Immune-inflammatory responses in the elderly: an update. Immun Ageing 2018; 15: 11.
[http://dx.doi.org/10.1186/s12979-018-0117-8] [PMID: 29507595]
[10]
Nikolich-Žugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol 2018; 19(1): 10-9.
[http://dx.doi.org/10.1038/s41590-017-0006-x] [PMID: 29242543]
[11]
Pawelec G. Hallmarks of human “immunosenescence”: adaptation or dysregulation? Immun Ageing 2012; 9(1): 15.
[http://dx.doi.org/10.1186/1742-4933-9-15] [PMID: 22830639]
[12]
Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol 2013; 14(5): 428-36.
[http://dx.doi.org/10.1038/ni.2588] [PMID: 23598398]
[13]
Pinti M, Appay V, Campisi J, et al. Aging of the immune system: focus on inflammation and vaccination. Eur J Immunol 2016; 46(10): 2286-301.
[http://dx.doi.org/10.1002/eji.201546178] [PMID: 27595500]
[14]
Attal N, Deback C, Gavazzi G, et al. Herpes Zoster and Functional Decline Consortium. Functional decline and herpes zoster in older people: an interplay of multiple factors. Aging Clin Exp Res 2015; 27(6): 757-65.
[http://dx.doi.org/10.1007/s40520-015-0450-0] [PMID: 26440662]
[15]
Janssens JP. Pneumonia in the elderly (geriatric) population. Curr Opin Pulm Med 2005; 11(3): 226-30.
[PMID: 15818184]
[16]
Weinberger B. Vaccines for the elderly: current use and future challenges. Immun Ageing 2018; 15: 3.
[http://dx.doi.org/10.1186/s12979-017-0107-2] [PMID: 29387135]
[17]
Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. Immunology 2013; 140(1): 22-30.
[http://dx.doi.org/10.1111/imm.12117] [PMID: 23621371]
[18]
Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin Immunol 2018; 39: 14-21.
[http://dx.doi.org/10.1016/j.smim.2018.05.001] [PMID: 29801750]
[19]
Haynes L, Eaton SM, Burns EM, Rincon M, Swain SL. Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J Immunol 2004; 172(9): 5194-9.
[http://dx.doi.org/10.4049/jimmunol.172.9.5194] [PMID: 15100256]
[20]
Sharma S, Dominguez AL, Hoelzinger DB, Lustgarten J. CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged. Cancer Immunol Immunother 2008; 57(4): 549-61.
[http://dx.doi.org/10.1007/s00262-007-0393-1] [PMID: 17828396]
[21]
Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198(5): 650-8.
[http://dx.doi.org/10.1086/590434] [PMID: 18652550]
[22]
Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200(2): 172-80.
[http://dx.doi.org/10.1086/599790] [PMID: 19508159]
[23]
Ott G, Barchfeld GL, Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995; 13(16): 1557-62.
[http://dx.doi.org/10.1016/0264-410X(95)00089-J] [PMID: 8578842]
[24]
Ansaldi F, Zancolli M, Durando P, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010; 28(25): 4123-9.
[http://dx.doi.org/10.1016/j.vaccine.2010.04.030] [PMID: 20433807]
[25]
Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine 2013; 31(50): 6030-3.
[http://dx.doi.org/10.1016/j.vaccine.2013.09.063] [PMID: 24095882]
[26]
Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12(1): 36-44.
[http://dx.doi.org/10.1016/S1473-3099(11)70295-X] [PMID: 22032844]
[27]
Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004; 5(10): 975-9.
[http://dx.doi.org/10.1038/ni1116] [PMID: 15454920]
[28]
Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy 2009; 1(6): 949-64.
[http://dx.doi.org/10.2217/imt.09.70] [PMID: 20563267]
[29]
Tan SY, Cavanagh LL, d’Advigor W, Shackel N, Fazekas de St Groth B, Weninger W. Phenotype and functions of conventional dendritic cells are not compromised in aged mice. Immunol Cell Biol 2012; 90(7): 722-32.
[http://dx.doi.org/10.1038/icb.2011.104] [PMID: 22231652]
[30]
You J, Dong H, Mann ER, Knight SC, Yaqoob P. Ageing impairs the T cell response to dendritic cells. Immunobiology 2013; 218(8): 1077-84.
[http://dx.doi.org/10.1016/j.imbio.2013.02.002] [PMID: 23582781]
[31]
Metcalf TU, Cubas RA, Ghneim K, et al. Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors. Aging Cell 2015; 14(3): 421-32.
[http://dx.doi.org/10.1111/acel.12320] [PMID: 25728020]
[32]
Lal H, Cunningham AL, Godeaux O, et al. ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372(22): 2087-96.
[http://dx.doi.org/10.1056/NEJMoa1501184] [PMID: 25916341]
[33]
Schulz AR, Mälzer JN, Domingo C, et al. Low thymic activity and dendritic cell numbers are associated with the immune response to primary viral infection in elderly humans. J Immunol 2015; 195(10): 4699-711.
[http://dx.doi.org/10.4049/jimmunol.1500598] [PMID: 26459351]
[34]
Dowling DJ, Levy O. Pediatric vaccine adjuvants: components of the modern vaccinologist’s toolbox. Pediatr Infect Dis J 2015; 34(12): 1395-8.
[http://dx.doi.org/10.1097/INF.0000000000000893] [PMID: 26353029]
[35]
Huang H, Ostroff GR, Lee CK, Wang JP, Specht CA, Levitz SM. Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and toll-like receptor agonists. Infect Immun 2009; 77(5): 1774-81.
[http://dx.doi.org/10.1128/IAI.00086-09] [PMID: 19273561]
[36]
Shaw AC, Panda A, Joshi SR, Qian F, Allore HG, Montgomery RR. Dysregulation of human Toll-like receptor function in aging. Ageing Res Rev 2011; 10(3): 346-53.
[http://dx.doi.org/10.1016/j.arr.2010.10.007] [PMID: 21074638]
[37]
Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6(8): 769-76.
[http://dx.doi.org/10.1038/ni1223] [PMID: 15995707]
[38]
Zhu Q, Egelston C, Gagnon S, et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 2010; 120(2): 607-16.
[http://dx.doi.org/10.1172/JCI39293] [PMID: 20101095]
[39]
Wells JW, Cowled CJ, Farzaneh F, Noble A. Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity. J Immunol 2008; 181(5): 3422-31.
[http://dx.doi.org/10.4049/jimmunol.181.5.3422] [PMID: 18714014]
[40]
Tye GJ, Ioannou K, Amofah E, et al. The combined molecular adjuvant CASAC enhances the CD8+ T cell response to a tumor-associated self-antigen in aged, immunosenescent mice. Immun Ageing 2015; 12: 6.
[http://dx.doi.org/10.1186/s12979-015-0033-0] [PMID: 26157468]
[41]
Gambino CM, Vasto S, Ioannou K, et al. Triggering of Toll-like receptors in the elderly. A pilot study relevant for vaccination.In: Updates in Pathobiology: causality and chance in ageing, age-related diseases and longevity. Palermo University Press 2017.
[42]
Panda A, Qian F, Mohanty S, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol 2010; 184(5): 2518-27.
[http://dx.doi.org/10.4049/jimmunol.0901022] [PMID: 20100933]
[43]
Baldwin HM, Ito-Ihara T, Isaacs JD, Hilkens CM. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. Ann Rheum Dis 2010; 69(6): 1200-7.
[http://dx.doi.org/10.1136/ard.2009.110502] [PMID: 19773288]
[44]
Liu WM, Nahar TE, Jacobi RH, et al. Impaired production of TNF-α by dendritic cells of older adults leads to a lower CD8+ T cell response against influenza. Vaccine 2012; 30(9): 1659-66.
[http://dx.doi.org/10.1016/j.vaccine.2011.12.105] [PMID: 22230585]
[45]
Sánchez-Ramón S, Conejero L, Netea MG, Sancho D, Palomares Ó, Subiza JL. Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations. Front Immunol 2018; 9: 2936.
[http://dx.doi.org/10.3389/fimmu.2018.02936] [PMID: 30619296]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 39
Year: 2019
Page: [4163 - 4167]
Pages: 5
DOI: 10.2174/1381612825666191111155800
Price: $65

Article Metrics

PDF: 17
HTML: 4